{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:28:42Z","timestamp":1790252922723,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP13\/00187"],"award-info":[{"award-number":["CP13\/00187"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Programa\u2010I3SNS"],"award-info":[{"award-number":["Programa\u2010I3SNS"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["AC\u20100095\u20102013"],"award-info":[{"award-number":["AC\u20100095\u20102013"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,6]]},"abstract":"Summary<\/jats:title>Little data are available on renal toxicity exerted by direct\u2010acting antivirals (DAA<\/jats:styled-content>s) in real life. The aim of this study was to assess the impact of direct\u2010acting antivirals against hepatitis C virus infection currently used in Spain and Portugal on the estimated glomerular filtration rate (eGFR<\/jats:styled-content>) in clinical practise. From an international, prospective multicohort study, patients treated with DAA<\/jats:styled-content>s for at least 12\u00a0weeks and with eGFR<\/jats:styled-content> \u226530\u00a0mL\/min per 1.73\u00a0m2<\/jats:sup> at baseline were selected. eGFR<\/jats:styled-content> was determined using the CKD<\/jats:styled-content>\u2010EPI<\/jats:styled-content> formula. A total of 1131 patients were included; 658 (58%) were HIV<\/jats:styled-content>\/HCV<\/jats:styled-content>\u2010coinfected patients. Among the 901 patients treated for 12\u00a0weeks, median (interquartile range) eGFR<\/jats:styled-content> was 100 (87\u2010107) at baseline vs 97 (85\u2010105) mL\/min per 1.73\u00a0m2<\/jats:sup> at week 12 of follow\u2010up (FU<\/jats:styled-content>12) post\u2010treatment (P<\/jats:italic>\u00a0<\u00a0.001). For HIV<\/jats:styled-content>\u2010coinfected subjects who received tenofovir plus a ritonavir\u2010boosted HIV<\/jats:styled-content> protease inhibitor (PI<\/jats:styled-content>\/r), baseline vs FU<\/jats:styled-content>12 eGFR<\/jats:styled-content> were 104 (86\u2010109) vs 104 (91\u2010110) mL\/min per 1.73\u00a0m2<\/jats:sup> (P<\/jats:italic>\u00a0=\u00a0.913). Among subjects receiving ombitasvir\/paritaprevir with or without dasabuvir, eGFR<\/jats:styled-content> did not show any significant change. Of 1100 subjects with eGFR<\/jats:styled-content> >60\u00a0mL\/min per 1.73\u00a0m2<\/jats:sup> at baseline, 22 (2%) had eGFR<\/jats:styled-content> <60\u00a0mL\/min per 1.73\u00a0m2<\/jats:sup> at FU<\/jats:styled-content>12, but none presented with eGFR<\/jats:styled-content> <30\u00a0mL\/min per 1.73\u00a0m2<\/jats:sup>. In conclusion, eGFR<\/jats:styled-content> slightly declines during therapy with all\u2010oral DAA<\/jats:styled-content>s and this effect persists up to 12\u00a0weeks after stopping treatment in subjects with normal to moderately impaired renal function, regardless of HIV<\/jats:styled-content> status. Concomitant use of tenofovir plus PI<\/jats:styled-content>\/r does not seem to have an impact on eGFR<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/jvh.12867","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T20:04:16Z","timestamp":1517256256000},"page":"699-706","source":"Crossref","is-referenced-by-count":17,"title":["Impact of interferon\u2010free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real\u2010life cohort"],"prefix":"10.1111","volume":"25","author":[{"given":"M. J.","family":"\u00c1lvarez\u2010Ossorio","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases and Microbiology Hospital Universitario de Valme Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sarmento e Castro","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Centro Hospitalar do Porto Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Granados","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario de Gran Canaria Dr Negr\u00edn Las Palmas de Gran Canaria Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-790X","authenticated-orcid":false,"given":"J.","family":"Mac\u00edas","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Microbiology Hospital Universitario de Valme Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. E.","family":"Morano\u2010Amado","sequence":"additional","affiliation":[{"name":"Unit of Infectious Pathology Hospital Universitario Alvaro Cunqueiro Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"R\u00edos","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario Virgen Macarena Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Merino","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Complejo Hospitalario Universitario de Huelva Huelva Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. N.","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Hospital Universitario Virgen de la Victoria Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Collado","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Hospital Universitario Torrec\u00e1rdenas Almeria Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rez\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital La L\u00ednea AGS Campo de Gibraltar Cadiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"T\u00e9llez","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Microbiology Hospital Universitario de Puerto Real Instituto de Investigaci\u00f3n e Innovaci\u00f3n en Ciencias Biom\u00e9dicas de la Provincia de C\u00e1diz (INiBICA) Puerto Real Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Hospital Universitario de Gran Canaria Dr Negr\u00edn Las Palmas de Gran Canaria Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Centro Hospitalar do Porto Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0296","authenticated-orcid":false,"given":"J. A.","family":"Pineda","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Microbiology Hospital Universitario de Valme Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-1013","authenticated-orcid":false,"given":"K.","family":"Neukam","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Microbiology Hospital Universitario de Valme Seville Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the HEPAVIR\u2010DAA, GEHEP\u2010MONO, RIS\u2010HEP07 and RIS\u2010HEP13 Study Groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i32.1343"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26602"},{"key":"e_1_2_7_4_1","unstructured":"NeukamK Mac\u00edasJ SantosJ et\u00a0al.Decrease of the estimated glomerular filtration rate during direct\u2010acting antiviral\u2010based therapy.XIX Congreso Nacional de la Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC). May 28\u201030 2015.Seville Spain. Abstract 183."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835fac51"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000042"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040245"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833b1b26"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu107"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.08.031"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0132-1"},{"key":"e_1_2_7_12_1","unstructured":"Gilead Sciences Ltd Harvoni Summary of Product Characteristics Gilead Sciences Ltd 2014. Available at:https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/harvoni\/harvoni_pi.pdf.. Accessed January 10th 2017."},{"key":"e_1_2_7_13_1","unstructured":"ChanAW ParkL CollinsLF et\u00a0al.Correlation of renal biomarkers and tenofovir AUC in the ION\u20104 study cohort.17th Conference on Retroviruses and Opportunistic Infections. Seattle USA February 13\u201016 2017. Abstract 138."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19583"},{"key":"e_1_2_7_15_1","unstructured":"European Association for the Study of the Liver (EASL).EASL Recommendations on Treatment of Hepatitis C 2016.http:\/\/www.easl.eu\/medias\/cpg\/HCV2016\/Summary.pdf. Accessed January 10th 2017."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_7_17_1","unstructured":"The National Kidney Foundation: Chronic Kidney Disease Stages. Available at:https:\/\/www.kidney.org\/. Accessed February 221st 2017."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13336"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12681"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13837"},{"key":"e_1_2_7_21_1","volume-title":"Treatment With Ombitasvir\/Paritaprevir\/r Plus Dasabuvir With Ribavirin Was Not Associated With Changes in Renal Function: An Analysis of 1211 Patients Enrolled in Four Phase 2 and 3 Trials","author":"Jacobson IM","year":"2015"},{"key":"e_1_2_7_22_1","volume-title":"Effectiveness of HCV Antiviral Treatment in Patients with Cirrhosis or Advanced Fibrosis and End\u2010Stage Kidney Disease on Dialysis","author":"Ponziani FR"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9684-3"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100790"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00211-8"},{"key":"e_1_2_7_26_1","volume-title":"Improved Renal Laboratory Parameters in CHB Patients Treated with TAF Compared with TDF","author":"Agarwal K","year":"2016"},{"key":"e_1_2_7_27_1","unstructured":"Vivancos\u2010GallegoMJ MorenoA P\u00e9rez\u2010EliasMJ et\u00a0al.Real\u2010life renal safety of \u201cboosted TDF\u201d in HIV\/HCV\u2010patients on SOF\/LDV.16th Conference on Retroviruses and Opportunistic Infections. Boston USA February 22\u201025 2016. Abstract 452."},{"key":"e_1_2_7_28_1","unstructured":"MendezJ Gon\u00e7alvesC MarquesM et\u00a0al.Glomerular filtration rate change during HCV with sofosbuvir\/ledipasvir in HCV\/HIV coinfected patients treated with tenofovir \u00b1 boosted protease inhibitor.The Liver Meeting Boston USA. November 2016. Abstract 1959."}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:33:55Z","timestamp":1695490435000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/jvh.12867"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12867","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]}}}